悦康药业(688658.SH)：子公司YKYY032注射液获得国家药品监督管理局和FDA临床试验批准

Core Viewpoint - YKYY032 injection has received approval for clinical trials in China and the United States for the treatment of hyperlipoproteinemia(a) [1] Group 1: Regulatory Approvals - The company’s subsidiary, Beijing YKYY Technology Co., Ltd., and Hangzhou Tianlong Pharmaceutical Co., Ltd. have obtained the clinical trial approval notice from the National Medical Products Administration for YKYY032 injection [1] - The company has also received a "Study May Proceed Letter" from the U.S. Food and Drug Administration, allowing clinical trials for YKYY032 injection [1] Group 2: Drug Mechanism and Efficacy - YKYY032 injection is a chemically synthesized double-stranded siRNA drug that utilizes RNA interference to specifically silence the mRNA of the LPA gene, thereby blocking the generation of lipoprotein(a) [Lp(a)] [1] - Preclinical studies have shown that the drug exhibits significant pharmacological activity both in vitro and in vivo, effectively reducing LPA mRNA and Lp(a) protein levels in various animal models [1] - In non-human primates, the drug has also been associated with reductions in LDL-C and ApoB levels, demonstrating a good and lasting lipid-lowering effect [1] Group 3: Safety and Tolerability - Repeated dosing toxicity studies have confirmed that YKYY032 injection possesses good safety and tolerability [1]